Frontiers in Cardiovascular Medicine最新文献

{"title":"Chinese medicine targets cellular autophagy against cardiovascular diseases: research progress and future prospects.","authors":"Zhengyu Chen, Jinjin Dou, Xiwu Zhang","doi":"10.3389/fcvm.2025.1585407","DOIUrl":"10.3389/fcvm.2025.1585407","url":null,"abstract":"<p><p>Cardiovascular diseases (CVDs) pose a serious threat to human health and represent one of the leading causes of death worldwide. Cellular autophagy, an essential intracellular self-degradation and homeostasis maintenance mechanism, plays a pivotal role in the pathogenesis of cardiovascular diseases. Traditional Chinese Medicine (TCM), with its unique theoretical framework and therapeutic principles, has demonstrated remarkable efficacy in CVDs management, garnering increasing scientific attention. In recent years, growing research attention has focused on TCM's autophagy regulation for CVDs treatment. However, most studies remain limited to cellular and animal models, with insufficient clinical data and unclear specific metabolic pathways and targets. Therefore, it is imperative to (1) investigate autophagy mechanisms in depth (2), explore methods for autophagy balance, and (3) clarify drug interactions to establish a foundation for clinical applications. This article comprehensively summarizes relevant research findings, provides an in-depth discussion of TCM's mechanisms in autophagy regulation for CVDs treatment, reviews current research status, and outlines future development trends, aiming to offer valuable theoretical foundations and therapeutic strategies for clinical CVDs management.</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"12 ","pages":"1585407"},"PeriodicalIF":2.8,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12146376/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144257743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between different hemoglobin glycation index and prognosis in patients with a first diagnosis of acute myocardial infarction: a retrospective study based on the MIMIC-IV database.","authors":"Dong Chen, Ben Hu, Xing-Hua Chen, Xing Wei, Jun Feng, Ze-Ping Hu","doi":"10.3389/fcvm.2025.1447420","DOIUrl":"10.3389/fcvm.2025.1447420","url":null,"abstract":"<p><strong>Background: </strong>The hemoglobin glycation index (HGI) is defined as the difference between the observed and predicted values of glycosylated hemoglobin (HbA1c), which is closely associated with a variety of poor prognoses. However, the relationship between HGI and short-term mortality risk in patients with a first diagnosis of acute myocardial infarction (AMI) remains unclear. This study aims to provide a better understanding of the relationship between HGI and mortality risk in patients with a first diagnosis of AMI.</p><p><strong>Methods: </strong>We conducted a cohort study using data from 1,961 patients with a first diagnosis of AMI from the Medical Information Mart for Intensive Care IV (MIMIC-IV; version 2.2) database. Patients were divided into four groups based on HGI quartiles. A Cox proportional hazards model and a two-segmented Cox proportional hazards model were used to elucidate the non-linear relationship between HGI in patients with a first diagnosis of AMI and mortality.</p><p><strong>Results: </strong>Of the surveyed population, 175 patients (8.92%) died within 90 days, and 210 patients (10.71%) died within 180 days. A low HGI was significantly associated with 90-day mortality [HR, 1.99; 95% CI (1.22, 3.08); <i>P</i> < 0.001] and 180-day mortality [HR, 1.74; 95% CI (1.18, 2.43); <i>P</i> < 0.001] in patients with a first diagnosis of AMI in the completely adjusted Cox proportional risk model, showing a non-linear correlation with an inflection point at 0.16 and 0.44. In the subgroup analysis, patients with prediabetes mellitus (pre-DM) and lower HGI levels had increased 90-day [HR, 8.30; 95% CI (2.91, 23.68)] and 180-day mortality risks [HR, 6.84; 95% CI (2.86, 16.34)].</p><p><strong>Conclusion: </strong>There is a significant correlation between HGI and all-cause mortality in patients diagnosed with AMI, especially those with lower HGI. HGI can serve as a potential indicator for evaluating the 90 and 180-day death risk of such patients.</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"12 ","pages":"1447420"},"PeriodicalIF":2.8,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12146337/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144257733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A multi-center, open label, single group, observational clinical trial to investigate the effects of training on the administration of Cardioplexol™.","authors":"Hendrik T Tevaearai Stahel, Niuscha Taheri, Andreas Winkler, Johannes Hohlfeld, Wolfgang Dietl, Christoph Starck, Arnaud Van Linden, Jan Bidovec, Aaron Imhof, Thierry P Carrel, Bernard Voet, Thomas Walther, Rainald Seitelberger, Michael Grimm, Christoph Holzinger, Martin Grabenwöger","doi":"10.3389/fcvm.2025.1588088","DOIUrl":"10.3389/fcvm.2025.1588088","url":null,"abstract":"<p><strong>Introduction: </strong>Cardioplexol™ was recently proven effective and non-inferior to Buckberg's solution in a pivotal Phase-3 clinical trial. We hypothesized here that a standardized training program for surgeons without prior experience of Cardioplexol™ could increase its administration reliability and participate to its overall benefit.</p><p><strong>Methods: </strong>Open label, single group, observational study involving 29 surgeons from 7 centers in 3 countries. The training program included a theoretical part, and two surgical procedures performed under trainer supervision. In a subsequent evaluation part, surgeons operated on 4 additional patients. The number of major deviations from the pre-defined administration protocol (incorrect volume of initial/second/third/fourth dose, incorrect duration of injection of initial dose, incorrect timing of application of initial/second/third/fourth dose) was set as primary endpoint.</p><p><strong>Results: </strong>A total of 171 patients were screened of which 157 were operated on (57 in the training part and 100 in the evaluation part). No major deviations were observed. Other outcomes, including postoperative TnT and CK-MB profiles, cumulative inotropic support provided during the first 24 h after myocardial reperfusion, cardiac conversion rate, ICU length of stay, were all similar to or better than the results observed in the previous pivotal study.</p><p><strong>Conclusion: </strong>Cardiac surgeons not familiar to Cardioplexol™ benefit from a structured and supervised training. This kind of training contributes to improve the efficiency and safety of a new cardioplegic solution such as Cardioplexol™.</p><p><strong>Trial registration: </strong>[ClinicalTrials.gov]: identifier [NCT03823521, and EudraCT No: 2018-002311-10].</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"12 ","pages":"1588088"},"PeriodicalIF":2.8,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12146177/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144257732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Methods and validity indicators for measuring adherence and persistence to aspirin in secondary cardiovascular prevention: a systematic review.","authors":"Rauf Nouni-García, Elisabeth Ramirez-Familia, Adriana López-Pineda, Amanda Esquerdo-Arroyo, Álvaro Carbonell-Soliva, María Martínez-Muñóz, Antonio F Compañ Rosique, Jose A Quesada, Concepción Carratalá-Munuera, Vicente F Gil-Guillén","doi":"10.3389/fcvm.2025.1570331","DOIUrl":"10.3389/fcvm.2025.1570331","url":null,"abstract":"<p><strong>Background: </strong>Aspirin (acetylsalicylic acid, ASA) is widely recommended for long-term secondary cardiovascular prevention (SCP), but its clinical effectiveness depends on patient adherence, which remains suboptimal. Understanding how adherence and persistence to ASA are measured is essential to improving outcomes. This systematic review aimed to identify the methods used to assess adherence and persistence to ASA in SCP and evaluate their validity indicators.</p><p><strong>Methods: </strong>We systematically searched EMBASE, MEDLINE, and Scopus for studies published up to October 30, 2023, reporting methods for measuring adherence or persistence to ASA in adults undergoing secondary cardiovascular prevention. Two reviewers independently screened articles and extracted data on study characteristics, measurement methods, and validity indicators. The results were synthesized in tabular form according to method type (indirect or direct) and outcome assessed (adherence or persistence). Risk of bias was evaluated for studies that conducted validation analyses of the measurement methods.</p><p><strong>Results: </strong>Forty studies were included, most conducted in the United States. Indirect methods predominated: self-report questionnaires (45%, <i>n</i> = 18) and pharmacy dispensing records (32.5%, <i>n</i> = 13) were the most common tools for assessing adherence. Direct methods, such as platelet function tests or biochemical assays, were less frequently used (25%, <i>n</i> = 10). For persistence, dispensing records were the most used method (70%, <i>n</i> = 7). No indirect method reported validation specifically for ASA adherence or persistence. Validity indicators were only partially available for some direct methods.</p><p><strong>Conclusions: </strong>Adherence and persistence to ASA in SCP are primarily measured through indirect methods, with a lack of specific validation for ASA. There is a critical need to develop standardized, validated tools that integrate both direct and indirect measures and address gender-specific barriers to adherence.</p><p><strong>Systematic review registration: </strong>https://www.crd.york.ac.uk/PROSPERO/view/CRD42023470993, PROSPERO identifier CRD42023470993.</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"12 ","pages":"1570331"},"PeriodicalIF":2.8,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12146176/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144257744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pressure-strain product reflects left ventricular stroke work under a wide range of left ventricular assist device support levels.","authors":"Kei Sato, Yuki Yoshida, Shohei Yokota, Hiroki Matsushita, Hidetaka Morita, Masafumi Fukumitsu, Takuya Nishikawa, Kazunori Uemura, Toru Kawada, Keita Saku","doi":"10.3389/fcvm.2025.1566021","DOIUrl":"10.3389/fcvm.2025.1566021","url":null,"abstract":"<p><strong>Introduction: </strong>Assessment of native cardiac function is vital in patients with cardiogenic shock supported by a left ventricular assist device (LVAD), as it is directly related to the critical decision of LVAD management. Left ventricular stroke work (LVSW) can be useful for cardiac assessment to predict survival in cardiogenic shock patients; however, this measurement cannot necessarily be obtained under LVAD support, especially in cases where the aortic valve is closed (i.e., total support). Therefore, we propose a novel echocardiographic parameter named the pressure-strain product (PSP), the product of left ventricular (LV) pressure and LV myocardial strain, as this measurement can be calculated even under LV total support. This study aimed to investigate whether PSP was correlated with pressure-volume (PV) loop-based LVSW and myocardial oxygen consumption under LVAD support.</p><p><strong>Method: </strong>We used 15 adult goats. An LVAD system was established during open chest surgery by draining blood from the left ventricle and returning it to the carotid artery. LV PV loops were analyzed by measuring LV pressure and volume using sonomicrometry. PV loop-based LVSW was defined as the area surrounded by PV loops. The PSP was defined as the product of the peak LV pressure and global circumferential strain (GCS) using speckle-tracking echocardiography. LVAD support levels were divided into three groups: control, and partial (with residual native cardiac output) and total (without native cardiac output) support. Myocardial oxygen consumption was measured using coronary flow and blood gas analyses. The correlation coefficient was measured using linear regression analysis.</p><p><strong>Results: </strong>According to each LVAD support level at control, partial support, and total support, LVSW was 1,748 ± 867, 840 ± 467, and 290 ± 262 mmHg·ml, while PSP was 2,341 ± 507, 1,836 ± 768, and 539 ± 269 mmHg·%, respectively. PSP (<i>r</i> = 0.54) showed the strongest correlation with PV loop-based LVSW among other echocardiographic parameters, including LV end-diastolic volume (<i>r</i> = 0.37), GCS (<i>r</i> = 0.40), and echo-based LVSW (<i>r</i> = 0.50). PSP level was significantly associated with myocardial oxygen consumption (<i>r</i> = 0.55).</p><p><strong>Conclusion: </strong>PSP significantly correlated with PV loop-based LVSW at various LVAD support levels. PSP can be a non-invasive parameter for assessing myocardial metabolism under LVAD support, potentially reflecting myocardial oxygen consumption.</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"12 ","pages":"1566021"},"PeriodicalIF":2.8,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12141206/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144247271","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pre-procedural abnormal von Willebrand factor function predicts clinical outcomes after Transcatheter Aortic Valve Implantation: a prospective cohort study.","authors":"Haitham Abu Khadija, Mohammad Alnees, Omar Ayyad, Gera Gandelman, Nizar Abu Hamdeh, Amir Haim, Yazan Hamdan, Ramon Cohen, Duha Najajra, Alena Kirzhner, Tal Schiller, Jacob George, Alex Blatt","doi":"10.3389/fcvm.2025.1576921","DOIUrl":"10.3389/fcvm.2025.1576921","url":null,"abstract":"<p><strong>Background and objectives: </strong>Transcatheter Aortic Valve Implantation (TAVI) is a minimally invasive intervention for aortic stenosis, which is associated with the potential for major vascular complications and arrhythmias. This study aims to identify primary predictors of these complications, emphasizing the roles of Decreased Platelet Count (DPC) and Acquired Von Willebrand Syndrome (AVWS).</p><p><strong>Methods: </strong>We performed a prospective study with 80 patients planning to receive TAVI at the Heart Center, Kaplan Medical Center, Rehovot, Israel. Pre-procedural evaluations include the measurement of baseline platelet counts and the functionality of the von Willebrand factor. The DPC was determined as the percentage decreased from baseline to the lowest count. AVWS was diagnosed through the assessment of von Willebrand factor activity and antigen concentrations.</p><p><strong>Results: </strong>Our results demonstrate that both DPC and AVWS are crucial predictors of major vascular complications. Specifically, patients with a DPC exceeding 20% exhibited a coefficient (Coef) of 1.276 (<i>p</i> = 0.072; 95% CI: -0.116 to 2.668) for complications. While, patients with abnormal von Willebrand factor function presented an Coef of 1.841 (<i>p</i> = 0.022; 95% CI: 0.271-3.410) for complications compared to those without AVWS. ROC curve analysis indicated an AUC of 0.7417 for the DPC model and 0.8025 for the AVWS model in predicting major vascular complications. In the arrhythmia model, AVWS appeared as a significant predictor of arrhythmias, with an OR of 4.480 [95% CI: (1.21, 16.49), <i>p</i> = 0.024].</p><p><strong>Conclusions: </strong>Assessing both DPC and von Willebrand factor function is crucial for predicting post-TAVI complications.</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"12 ","pages":"1576921"},"PeriodicalIF":2.8,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12141306/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144247270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The vasodilatory effect of acupuncture and medicine-cake-separated moxibustion on a 28-year course of Takayasu arteritis: a case report.","authors":"Zheqi Wang, Gao Sang, Feijin Lin, Yingjun Liu","doi":"10.3389/fcvm.2025.1562746","DOIUrl":"10.3389/fcvm.2025.1562746","url":null,"abstract":"<p><strong>Introduction: </strong>Large vessel vasculitis (LVV) is a complex inflammatory condition that primarily affects large blood vessels, leading to stenosis or occlusion and thereby disrupting normal blood flow. This case study presents a 71-year-old female Asian patient who experienced recurrent dyspnea and generalized fatigue since 1996 and was diagnosed with Takayasu arteritis (TAK) in 2000. Despite undergoing multiple interventions, her symptoms persisted. In 2008, she began treatment with acupuncture and medicine-cake-separated moxibustion. Specific local and distal acupoints were targeted, and moxibustion with earthworm powder cakes was applied, using 3-5 moxa cones per session. Significant improvements in fatigue and dyspnea were observed following three treatment sessions. Over half year period of continuous treatment, the patient experienced complete resolution of symptoms, including the return of the previously non-palpable left radial pulse. Imaging studies conducted in 2009, 2011, 2016, 2019, and 2022 showed increased blood flow in the left common carotid artery and the development of collateral circulation, along with symptom relief, thus confirming the stability of the condition.</p><p><strong>Case summary: </strong>This case study describes a female Asian patient, born in 1953, who experienced dyspnea and fatigue since 1996 and was diagnosed with TAK in 2000. She commenced treatment in 2008, which comprised acupuncture and medicine-cake-separated moxibustion. Following six courses of treatment, significant improvements in fatigue and dyspnea were noted. During the 14-year follow-up period, the patient experienced near-complete resolution of symptoms.</p><p><strong>Conclusion: </strong>This study underscores the significant improvement and sustained post-treatment effects of acupuncture combined with moxibustion using a separated medicine cake in managing late-stage LVV.</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"12 ","pages":"1562746"},"PeriodicalIF":2.8,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12141287/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144247273","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiac T1 mapping in non-ST-segment elevation myocardial infarction: temporal changes in myocardial fibrosis.","authors":"Luis Paiva, Maria João Ferreira, Sónia Afonso, Paulo Donato, Lino Gonçalves","doi":"10.3389/fcvm.2025.1563368","DOIUrl":"10.3389/fcvm.2025.1563368","url":null,"abstract":"<p><strong>Introduction: </strong>Cardiac magnetic resonance (CMR) imaging allows tracking of ongoing fibrosis modifications following myocardial infarction (MI). We evaluated temporal changes in late gadolinium enhancement (LGE) and extracellular volume fraction (ECV) within the MI culprit coronary artery and remote regions of the myocardium during the index ischemic event and follow-up in patients with NSTEMI.</p><p><strong>Methods: </strong>This prospective, single-center study included 30 patients with type 1 NSTEMI. It involved the evaluation of patients using coronary angiography, invasive coronary physiology, and biomarkers. CMR imaging was used to assess left ventricular (LV) volume, function, and myocardial fibrosis using LGE and ECV. These assessments were performed at baseline and repeated 6-10 months after MI.</p><p><strong>Results: </strong>At the 4-year post-MI follow-up, 27 patients survived [age 65 (58,74) years; 77% male], and LV mass, volume, and contractility remained unchanged between the baseline and follow-up measurements. Myocardial fibrosis assessed using LGE showed a decreasing trend at follow-up (9.4 ± 4.4% vs. 6.7 ± 4.4%; <i>p</i> = 0.051), particularly in the MI culprit coronary artery regions (14.2 ± 8.6% vs. 9.5 ± 7.0%; <i>p</i> = 0.015). LGE volume regression was observed in 70% of cases. The ECV measurements did not change between the initial and follow-up CMR assessments. Despite the high prevalence of multivessel coronary artery disease (CAD) (53%), no significant changes in LGE or ECV measurements were observed in the remote myocardium.</p><p><strong>Conclusions: </strong>After NSTEMI, LGE decreased in the heart regions supplied by the culprit coronary arteries. However, the ECV measurements remained unchanged. Multivessel CAD was not associated with significant changes in myocardial fibrosis in the remote myocardium.</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"12 ","pages":"1563368"},"PeriodicalIF":2.8,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12141208/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144247264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global ischemic heart disease burden attributable to kidney dysfunction from 1990 to 2021 and projections to 2050: results from the global burden of disease study 2021.","authors":"Meng Xia, Yingchao Shi, Hongtao Zhu, Yanan Ji","doi":"10.3389/fcvm.2025.1601549","DOIUrl":"10.3389/fcvm.2025.1601549","url":null,"abstract":"<p><strong>Background: </strong>Ischemic heart disease (IHD) is the leading cause of death of non-communicable diseases globally, presenting with particularly prominent metabolic risk associated with kidney dysfunction in the middle-aged and older populations. Accordingly, the present study intended to clarify trends in IHD burden attributable to kidney dysfunction from 1990 to 2021, with projection to 2050, in the middle-aged and older populations.</p><p><strong>Methods: </strong>This study quantified the burden of IHD attributable to kidney dysfunction in middle-aged and older populations from 1990 to 2021 through deaths, disability-adjusted life years (DALYs), and age-standardized rates (ASRs) based on the estimated annual percentage change (EAPC). Autoregressive integrated moving average (ARIMA) and exponential smoothing (ES) models were adopted to predict the changing trends of IHD burden attributable to kidney dysfunction from 2022 to 2050.</p><p><strong>Results: </strong>Between 1990 and 2021, both global deaths (from 0.83 million to 1.40 million) and DALYs (from 16.2 million to 26.1 million) from IHD attributable to kidney dysfunction increased in the studied populations. Despite rising absolute numbers, age-standardized death (ASDR) and DALY rates (ASDAR) declined significantly, with EAPC of -0.54 (95% CI: -0.97 to -0.11) and -0.55 (95% CI: -0.85 to -0.25) respectively, primarily driven by regions with high and high-middle SDI. Sex-specific analyses revealed steeper declines among females (ASDR EAPC: -1.71; ASDAR EAPC: -1.55) than males (ASDR EAPC: -1.18; ASDAR EAPC: -1.09), even with consistently higher rates in males. Age-stratified data showed peak ASRs in the >95 age group in 2021, despite consistent rate reductions across all age cohorts since 1990. Projections suggested continued growth in absolute burden through 2050, accompanied by sustained declines in ASDR and ASDAR, revealing both aging and improved age-adjusted disease management over time.</p><p><strong>Conclusion: </strong>This study suggests a decline in the global age-standardized IHD (ASDR/ASDAR) attributable to kidney dysfunction over three decades, yet accompanied by substantial absolute burden, disproportionately impacting lower SDI regions, males and the elderly. Projection to 2050 highlights a rising burden, necessitating prioritized resource allocation, enhanced health literacy, and evidence-based prevention targeting high-risk populations.</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"12 ","pages":"1601549"},"PeriodicalIF":2.8,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12141223/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144247269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of left ventricular regional myocardial function by layer-specific strain in female patients with hypothyroidism.","authors":"Xiao Ding, Xijun Zhang, Changhua Wei, Jianjun Yuan, Kaikai Shen, Yisa Wang, Haohui Zhu","doi":"10.3389/fcvm.2025.1489979","DOIUrl":"10.3389/fcvm.2025.1489979","url":null,"abstract":"<p><strong>Objective: </strong>This study aims to explore the value of layer-specific strain in evaluating the differences in left ventricular 18-segment myocardial function between female hypothyroidism patients and healthy controls.</p><p><strong>Methods: </strong>Thirty-two female hypothyroidism patients (hypothyroidism group, HG) with normal left ventricular global systolic function and 30 healthy female volunteers (control group, CG) underwent two-dimensional echocardiography. Offline analysis using EchoPAC113 software measured peak systolic circumferential strain (PCS) and peak systolic longitudinal strain (PLS). Layer-specific strain values (endocardium, mid-myocardium, epicardium) were compared between groups.</p><p><strong>Results: </strong>PLS of the endocardium (PLS-endo) of the posterior wall in the middle segments of the left ventricle in HG was lower than that in CG. PCS of the mid-myocardium (PCS-mid) and epicardium (PCS-epi) of all walls in the apical segments of the left ventricle in HG were lower than those in CG. In the middle segments of the left ventricle in HG, the PCS-epi of the anterior septum, PCS-mid and PCS-epi of the anterior wall, PCS-mid and PCS-epi of the inferior wall, and PCS-endo, PCS-mid, and PCS-epi of the lateral and posterior walls were lower than those in CG. In the basal segments of the left ventricle in HG, the PCS-mid and PCS-epi of the anterior wall, PCS-mid and PCS-epi of the posterior wall, PCS-epi of the inferior wall, and PCS-endo, PCS-mid, and PCS-epi of the lateral wall were lower than those in CG. The global circumferential strain (GCS) of the mid-myocardium and epicardium in the basal and apical segments, as well as all layers in the middle segment, was significantly lower in HG.</p><p><strong>Conclusions: </strong>The layer-specific strain values in the left ventricle in female patients with hypothyroidism differed from those of healthy female controls. When evaluating the left ventricular regional myocardial function in female patients with hypothyroidism, circumferential strain was, to a certain extent, more affected by thyroid hormone abnormalities than longitudinal strain.</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"12 ","pages":"1489979"},"PeriodicalIF":2.8,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12141225/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144247266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}